ELC22关于靶向治疗的文章题目摘要
ELC22（2022年欧洲肺癌大会）关于靶向治疗的文章题目摘要,重点关注几个新药的数据。靶向的文章显然没有免疫的多。后续会把重点喝关键的文章数据摘译。61P - Updated efficacy and ctDNA analysis of patients with TRK fusion lung cancer treated with larotrectinib。
110P - Updated efficacy and safety of entrectinib in patients (pts) with NTRK fusion-positive (NTRK-fp) NSCLC
112P-Entrectinib in Chinese (mainland China, Hong Kong, Taiwan) patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC and NTRK-fp solid tumours
21P - Sintilimab in combination with anlotinib in non-small cell lung cancer patients with uncommon EGFR mutations: A phase II, single-arm, prospective study
49P -?EGFR exon 20 insertion mutations in patients with locally advanced or metastatic NSCLC in the German prospective, CRISP Registry real-world cohort (AIO-TRK-0315)
52P - ROS1 aberrations in non-small cell lung cancer patients without rearrangements: Clinical and molecular characteristics
48P - Efficacy of osimertinib (osi) on (prevention of) bone metastases (mets) and skeletal related events (SREs) in patients (pts) with epidermal growth factor receptor mutated (EGFRm+) non-small cell lung cancer (NSCLC)
50P -?Clinical characteristics, treatment patterns and outcomes of EGFR exon 20 insertion and other EGFR mutations in Korean aNSCLC patients
47P -?Real-world outcomes of immune checkpoint inhibitors and selective RET inhibitors for RET fusion non-small cell lung cancer
78TiP - Clinical evaluation of NVL-520, a highly selective ROS1 inhibitor in patients with advanced ROS1-positive solid tumors: The phase I/II ARROS-1 study
158P -?Real-world management of patients with EGFR exon 20-mutant NSCLC in the precision oncology era: First report from the European EXOTIC registry
159P -?ReWARD study - Real-world ALK-resistance data: A single center experience
156TiP -?An open-label, single-arm, phase II study evaluating the efficacy and safety of niraparib combined with radiotherapy and teriprizumab in patients with recurrent small cell lung cancer
57P - Acquired concurrent EGFR T790M and driver gene resistance from EGFR-TKIs hampered osimertinib efficacy in advanced lung adenocarcinoma
56P - Simultaneous tissue and liquid next-generation sequencing after first-line EGFR tyrosine kinase inhibitors resistance in advanced non-small cell lung cancer
48P -?Efficacy of osimertinib (osi) on (prevention of) bone metastases (mets) and skeletal related events (SREs) in patients (pts) with epidermal growth factor receptor mutated (EGFRm+) non-small cell lung cancer (NSCLC)
49P -?EGFR exon 20 insertion mutations in patients with locally advanced or metastatic NSCLC in the German prospective, CRISP Registry real-world cohort (AIO-TRK-0315)
7MO -?Oritinib (SH-1028) a third-generation EGFR tyrosine kinase inhibitor in locally advanced or metastatic NSCLC patients with positive EGFR T790M: Results of a single-arm phase II trial
79TiP -?A phase I, open-label, dose escalation, confirmation, and expansion trial of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations
74TiP - Capmatinib plus osimertinib vs platinum-pemetrexed doublet chemotherapy as second-line therapy in patients with stage IIIB/IIIC/IV EGFR-mutant, T790M-negative, MET-amplified NSCLC
77TiP - TRUST-II: A global phase II study for taletrectinib in ROS1 fusion-positive lung cancer and other solid tumors
78TiP -?Clinical evaluation of NVL-520, a highly selective ROS1 inhibitor in patients with advanced ROS1-positive solid tumors: The phase I/II ARROS-1 study
76TiP - RMC-4630 and sotorasib for advanced KRASG12C NSCLC after failure of prior standard therapies: A phase II tria
页:
[1]